Poseida Therapeutics’ P-BCMA-ALLO1 Receives US FDA...
Category : Approval/Launch 18 September 2024Poseida Therapeutics’ P-BCMA-ALLO1 receives US FDA RMAT designation to treat relapsed/refracto...
Poseida Therapeutics’ P-BCMA-ALLO1 receives US FDA RMAT designation to treat relapsed/refracto...
Novo Nordisk Global Business Services launches safe pharmaceuticals disposal initiative for employee...
Halozyme announces US FDA approval of Roche's Tecentriq Hybreza with Enhanze for multiple types...
Overview Envision Pharma Group, a leading global technology solutions partner, has launched its n...
Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic S...